CytomX Therapeutics (CTMX) Total Liabilities (2014 - 2026)
CytomX Therapeutics' (CTMX) quarterly Total Liabilities came in at $39.4 million in Q1 2026, down 46.34% YoY from $73.4 million in Q1 2025, and down 25.01% on a QoQ basis from $52.6 million in Q4 2025.
CytomX Therapeutics (CTMX) Total Liabilities (2014 - 2026) Analysis & Trends
CytomX Therapeutics (CTMX) has 13 years of Total Liabilities data on file, last reported at $39.4 million in Q1 2026.
- Quarterly Total Liabilities fell 46.34% year-over-year to $39.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $39.4 million (down 46.34% YoY) and the FY2025 annual result came in at $52.6 million, down 56.56% from the prior year.
- Total Liabilities fell to $39.4 million in Q1 2026, from $52.6 million in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $346.6 million in Q4 2022 to a low of $39.4 million in Q1 2026.
- A 5-year average of $199.6 million and a median of $216.4 million in 2024 frame the typical range for Total Liabilities.
- Annual changes were most pronounced in 2022 — Total Liabilities grew 1.99% — and 2025, when it plunged 71.04%.
- Tracing CTMX's Total Liabilities over 5 years: stood at $346.6 million in 2022, then dropped by 28.1% to $249.2 million in 2023, then tumbled by 51.46% to $121.0 million in 2024, then sank by 56.56% to $52.6 million in 2025, then fell by 25.01% to $39.4 million in 2026.
- The last three Total Liabilities figures came in at $39.4 million (Q1 2026), $52.6 million (Q4 2025), and $50.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | CytomX Therapeutics | 732.14 Mn | 401.86 Mn | - | 79.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 79.16 Mn |
| Mar 31, 2026 | 39.41 Mn |
| Dec 31, 2025 | 52.56 Mn |
| Sep 30, 2025 | 50.87 Mn |
| Jun 30, 2025 | 55.15 Mn |
| Mar 31, 2025 | 73.45 Mn |
| Dec 31, 2024 | 120.99 Mn |
| Sep 30, 2024 | 162.43 Mn |
| Jun 30, 2024 | 190.45 Mn |
| Mar 31, 2024 | 216.37 Mn |
| Dec 31, 2023 | 249.24 Mn |
| Sep 30, 2023 | 272.41 Mn |
| Jun 30, 2023 | 294.21 Mn |
| Mar 31, 2023 | 321.27 Mn |
| Dec 31, 2022 | 346.64 Mn |
| Sep 30, 2022 | 307.03 Mn |
| Jun 30, 2022 | 314.62 Mn |
| Mar 31, 2022 | 326.56 Mn |
| Dec 31, 2021 | 339.87 Mn |
| Sep 30, 2021 | 340.80 Mn |